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Long-Term Results From MOPPEBVCAD Chemotherapy With Optional Limited
Radiotherapy in Advanced Hodgkin’s Disease
By Paolo G. Gobbi, Carla Pieresca, Maria L. Ghirardelli, Nicola Di Renzo, Massimo Federico, Francesco Merli,
Emilio Iannitto, Vincenzo Pitini, Giovanni Grignani, Amedea Donelli, Mario Carotenuto, Vittorio Silingardi,
and Edoardo Ascari for the Gruppo Italiano per lo Studio dei Linfomi
The purpose was to verify the 5-year results of the
MOPPEBVCAD chemotherapy regimen with limited radio-
therapy in relation to the promising preliminary data. Me-
chlorethamine, vincristine, procarbazine, prednisone, epi-
doxorubicin, bleomycin, vinblastine, lomustine, melphalan,
and vindesine were delivered according to a schedule de-
rived through hybridization, intensification, and shortening
of the corresponding alternating CAD/MOPP/ABV regimen.
Radiotherapy was restricted to sites of bulky involvement or
to areas that responded incompletely to chemotherapy. This
multicenter, controlled, nonrandomized trial involved 145
eligible patients. Radiotherapy was administered to 47 pa-
tients, 46 of whom were in complete remission after chemo-
therapy. Remissions were complete in 137 patients (94%),
partial in 4 (3%), and null in the remaining 4. Tumor-specific,
overall, relapse-free, and failure-free survival at 5 years were
0.89, 0.86, 0.82, and 0.78, respectively. Hematologic toxicity
was considerable, whereas nonhematologic side effects
were fully acceptable. Most of the unfavorable prognostic
factors lost their clinical weight. Only age and lymphocyte
depletion histologic type were statistically correlated with
major follow-up endpoints; performance status and bone
marrow involvement were subordinate to age. Seven pa-
tients developed a second cancer (including 3 myelodyspla-
sias). MOPPEBVCAD with selected radiotherapy is a highly
effective regimen in advanced Hodgkin’s disease. Early and
late toxicity are no more severe than what would be ex-
pected with other alternating or hybrid regimens. A compari-
son with ABVD, which is currently considered the standard
regimen for advanced Hodgkin’s disease, is needed.
r 1998 by The American Society of Hematology.
IN THE LAST DECADE, increasing evidence made it clearthat the treatment of advanced Hodgkin’s disease (HD)
should be based on two distinct chemotherapy (CT) regimens,
possibly combined with variable radiotherapy (RT), ie, MOPP
(mechlorethamine, vincristine, procarbazine, and prednisone)
and ABVD (doxorubicin, bleomycin, vinblastine, and dacarba-
zine). Both regimens have been tested on large patient series,
both achieve equivalent results,1,2 both are non–cross-resistant,3
and both have no better four- or five-drug variants.4-8
However, in the 1980s, clinical application of the mathemati-
cal model of Goldie and Coldman9 to the drug sensitivity of
tumor cells according to their spontaneous mutation rate led
many investigators to design CT schedules that alternated some
of the most effective regimens, chiefly MOPP and ABVD.
Therefore, together with the alternating MOPP/ABVD sched-
ule,10 many other similar combinations were designed, such as
MOPP/CABS,11 MOP-BAP,12 MOPP-CAVmP,13 BCVPP/
ABD,14 LOPP/EVAP,15 ChlVPP/PABIOE,16 but none of them
seemed to be superior to MOPP. In the Cancer and Leukemia
Group B randomized trial, MOPP/ABVD was as effective as
ABVD alone and more effective than MOPP with regard to
complete remission rate and failure-free survival, but it did not
show statistically significant better survival.17
The Goldie and Coldman model reached its extreme exploita-
tion in CT regimens that delivered, within each cycle, all the
drugs previously scheduled in alternating courses. This strategy
allowed tumor cells more exposure to drugs having different
mechanisms of action, which should also contribute to reducing
the chance that resistant cell clones develop and grow. To this
aim, the so-called hybrid regimens were designed, such as
MOPP/ABV,18 MA/MA,19 ChlVPP/EVA,20 and BEACOPP.21
So far, such hybrid protocols have not shown results clearly
superior to those obtained with their alternating counterparts or
even with ABVD alone, which, moreover, proved to be less
toxic during a short follow-up.22
In agreement with the ongoing evolution of CT for advanced
HD, in 1987 the Italian Lymphoma Study Group (GISL)
designed a shortened, hybridized, and intensified version of
Straus’ alternating regimen CAD/MOPP/ABV23 and combined
it with optional use of RT on very selected and limited areas.
The preliminary data on feasibility, early results, and toxicity of
this modified CT program were very encouraging.24
We report here the final results of this multicenter trial using
hybrid MOPP/EBV/CAD (or, simply, MOPPEBVCAD) CT,
with or without limited RT.
MATERIALS AND METHODS
Patient population. The criteria for enrollment in the study were
(1) unequivocal histologic diagnosis of HD; (2) age of 15 to 75 years;
(3) no previous treatment; and (4) advanced or unfavorably presenting
disease, defined as stage II B, III B, IV or subdiaphragmatic stage III A
with lymphocyte-depleted nodular sclerosis or lymphocyte-depletion
histologic types, or all histologic types of stage III2A. One hundred and
fifty-five patients were entered into the study between January 1, 1988
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and September 30, 1993, the date on which the trial was closed. Ten
patients were subsequently excluded from the series: 5 on account of
histologic reevaluation, which changed the diagnosis to anaplastic
large-cell (CD301) lymphoma (3 cases), T-cell–rich B-cell lymphoma
(1 patient), and undifferentiated anaplastic carcinoma of the thyroid (1
case), respectively, and 5 because of staging inaccuracy (2 cases with
actual stage IIA disease) or protocol violations (3 patients who received
1 or 2 cycles of MOPPEBVCAD then continued with either ABVD [2
cases] or MOPP [1 case] for reasons other than clinical, less frequent
administration, distance from the hospital, etc).
Therefore, a total of 145 patients were eligible for the study and their
clinical characteristics are listed in Table 1. The annual enrollment rate
also reflects the increasing number of institutions that joined the GISL
during the years of this investigation; the enrollment rate was as
follows: 8% (1988), 16% (1989), 19% (1990), 23% (1991), 20%
(1992), and 14% (first 9 months of 1993).
An exact estimate of the expected sample size of the study was not
made, because this protocol was part of a general plan that divided
treatment strategy into three different risk groups.25 A preliminary
report was published on the first 80 patients, who were evaluable at the
end of 1991, regarding the feasibility, tolerability, and early clinical
results of the study.24 At that time, the advisability of stopping the trial
and starting a randomized study to compare MOPPEBVCAD with one
of the best current regimens was clear. However, the GISL rate of
patient accrual was not sufficient to sustain a randomized study until
other groups began to cooperate.
Disease stage was investigated according to the requirements of the
Cotswolds Meeting.26 In particular, staging procedures routinely in-
volved chest roentgenogram, computed tomography of the thorax and
abdomen, ultrasonography of the abdomen, and bone marrow biopsy.
None of the patients was staged with exploratory laparotomy and
splenectomy. Every clinical, radiologic, or laboratory abnormality
found at pretreatment staging was retested at the end of treatment to
evaluate response.
In 1995, pathologists were called on to revise the histologic
assessment of all cases of their own center and to submit equivocal
specimens to two external pathologists; 27 cases underwent such
intercenter reevaluation.
Chemotherapy. The criteria for hybridization, dose intensification,
and schedule shortening through which MOPPEBVCAD was derived
from the alternating three-drug combination CAD/MOPP/ABV have
already been detailed elsewhere.24 Six cycles of chemotherapy were
planned. Drug doses and administration schedules are listed in Table 2,
which also reports drug-dose modifications according to blood counts.
Growth factors were not available until the end of 1991. However,
starting in 1992, their use was very restricted and they were used only in
Table 1. Clinical Characteristics of the Patients Studied
Characteristics No. %
Mean 6 1
SD
Total 145 100
Gender
Male 85 59
Female 60 41
Age (median, 35 yr; range,
16-75 yr)
15-19 17 12
20-29 43 29
30-39 27 19
40-49 27 19
50-59 10 7
60-69 17 11
70-75 4 3
Histology
Lymphocyte predomi-
nance 2 1
Nodular sclerosis 68 46
Lymphocyte depleted
nodular sclerosis 20 14
Mixed cellularity 42 30
Lymphocyte depletion 13 9
Stage
II B 45 31
III2 A 22 15
III B 39 27
IV A 11 8
IV B 28 19
Mediastinal bulk 47 32
Spleen involvement 29 20
Extranodal involvement
Bone marrow 22 15
Lung 9 6
Liver 6 4
Other visceral organs 3 2
Hb ,100 g/L 16 11 119 6 20
ESR .40 mm 1st hour 95 66 61.6 6 37.6
Serum LDH .450 U/L 33 23 400 6 225
Serum albumin ,30 g/dL 26 18 3.64 6 0.59
SNLG prognostic index .0.5 52 36 0.39 6 0.2
IDHD probability of surviving
at 5 yr 0.71 6 0.18
Table 2. MOPPEBVCAD Hybrid Regimen: Drug Doses and Time
Schedule, With Dose Reduction According to Blood Cell Counts
Drugs
Dose
(mg/m2) Route Days
Mechlorethamine (NH2) 6 IV 1 cycles 1, 3, and 5, only
Lomustine (CCNU) 100 Oral 1 cycles 2, 4, and 6, only
Vindesine (VDZ) 3 IV 1
Melphalan (Alk) 6 Oral 1-3
Prednisone (Pred) 40 Oral 1-14
Epidoxorubicin (Epi) 40 IV 8
Vincristine (VCR) 1.4 IV 8
Procarbazine (PCZ) 100 Oral 8-14
Vinblastine (VBL) 6 IV 15
Bleomycin (BLM) 10 IV 15
Leukocyte
Count
(109/L)
Platelet
Count
(109/L) Doses and Drugs
.4 .150 100% All drugs
3.000-3.999 100-149 100% VCR, BLM, Pred,
50% VBL, VDZ, Alk, HN2, Epi,
CCNU, PCZ
2.000-2.999 50-99 100% VCR, BLM, Pred
25% VDZ, VBL, Alk, NH2, Epi,
PCZ
0% CCNU
1.500-1.999 50-99 100% BLM, Pred
50% VCR
25% VDZ, VBL, Alk, NH2, Epi,
PCZ
0% CCNU
,1.500 ,50 No drugs: reevaluation after 1
wk
When leukocytes are less than 3.0 and/or platelets are less than
100 3 109/L before the start of a new cycle, a 1 week delay is preferred
to dose reductions.
Abbreviation: IV, intravenous.
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cases of severe febrile neutropenia. Dose intensity was calculated
according to the criteria reported by Hryniuk27 and the examples and
suggestions offered by DeVita et al.28
Radiotherapy. RT was not routinely associated with CT but was
administered to a limited number of patients and only to 1 or 2 selected
areas corresponding to previous bulky involvement or to masses that
were only slowly or partially reduced during CT. RT had to be
administered after CT and total doses could not exceed 35 Gy. The
decision to treat, which sites to treat, and which dose to deliver were left
to the clinicians and radiotherapists of each institution. In 4 patients, the
extensive initial involvement of supradiaphragmatic areas required truly
extended-field mantle RT.
Assessment of response and statistical analysis. Complete remis-
sion (CR) was defined as complete regression of measured lesions and
disappearance of all other objective evidence of lymphoma for at least 3
months. Partial remission (PR) consisted of a decrease of more than
50% in the sum of the products of the diameters of the measurable
lesions. No response (NR) was anything less than a 50% decrease in
measurable lesions. According to the Cotswolds Meeting recommenda-
tion,26 the category of unconfirmed or uncertain complete remission
(CR[u]) was accepted to denote patients in normal health with no
clinical evidence of HD but with some radiological abnormality in a site
of previous disease. However, uncertainty about the completeness of
such a remission had to be resolved within 6 months from the end of
therapy. The definition of bulky masses met the criteria coded in the
Cotswolds Meeting, ie, for a mediastinal mass, when its maximum
width exceeded one third of the internal transverse diameter of the
thorax at the level of the disc between T5 and T6 vertebrae and, for any
extramediastinal mass, when its largest diameter was greater than 10
cm. A mass was judged to respond slowly when less than a PR was
achieved after the third cycle in patients responding at least partially at
the end of chemotherapy.
The Scotland and Newcastle Lymphoma Group (SNLG) prognostic
index29 and the International Database on Hodgkin’s Disease (IDHD)30
estimate of the probability of surviving year by year were retrospec-
tively calculated for each patient according to the investigators’
guidelines. These parameters were used as synthetic risk predictors
derived from some of the most recent systematic investigations directed
at selecting the best prognostic factors in HD.
Toxicity was measured according to standard ECOG criteria.31
Overall survival (OS) was determined from the date of diagnosis to
the date of last observation or death (from any cause). The same time
frame was used to calculate tumor mortality (TM), with the exception of
censoring deaths occurring in complete remission of HD and not
directly due to therapy. Relapse-free survival (RFS) for complete
responders was measured from the date of therapy completion to the
date of last observation or relapse. Failure-free survival (FFS) was
computed from the start of treatment to one of the following events:
death from any cause, disease progression during treatment, no CR at
the end of treatment, or relapse.
Survival curves were calculated using the method of Kaplan and
Meier.32 Deaths due to causes other than HD or treatment were not
censored, except for RFS.33
Many clinical features were scrutinized singly at diagnosis to
evaluate their individual role in discriminating OS, RFS, and FFS. In
this univariate study, the Kaplan and Meier estimate was used for
qualitative variables, whereas a simple linear regression analysis
applied to the proportional hazard model34 was used for quantitative
parameters. A multiple regression analysis was then performed, within
the same proportional hazard model, to select the best clinical features
related to OS, RFS, and FFS, respectively. In these analyses, the SNLG
index and the IDHD estimate of the survival probability at 5 years were
used as single, distinct covariates.
RESULTS
Of the 145 eligible patients, 137 (94%) achieved CR, 136
with chemotherapy alone. Four obtained only a PR (3%) and the
other 4 did not respond at all (3%).
A total of 844 cycles were administered and evaluated; the
mean number of cycles per patient was 5.8 (range, 3 to 8). Six
patients received more than 6 cycles due to slowly responding
symptoms or adenomegalies. All but 1 of them reached CR.
In 18 patients, treatment was stopped before the sixth cycle
because of severe hematological toxicity (14 cases), infection (1
case of Pneumocystis carinii pneumonia and 1 of B-virus
hepatitis), or patient refusal of further therapy (2 cases). Four of
these 18 subjects died with persisting evidence of disease,
whereas another relapsed after 3 months of CR and died of the
disease during salvage treatment. The remaining 13 achieved
stable CR.
CT was administered on an outpatient basis in the great
majority of cases and only 18 subjects had to be hospitalized for
complications.
Dose intensity was 0.76 6 0.12 for the first 3 cycles and
0.72 6 0.11 over all 6 cycles. According to the criteria for dose
adjustment on the basis of white blood cell and platelet counts,
delaying therapy was preferred to decreasing drug doses if
severe myelosuppression occurred near the beginning of a new
cycle, whereas the opposite strategy was followed when
myelosuppression appeared before completion of the cycle. In
1992, growth factors became available in Italy, but the possibil-
ity of further dose intensification was not pursued. Granulocyte
colony-stimulating factor (G-CSF) and granulocyte-macro-
phage colony-stimulating factor (GM-CSF) were used strictly
on clinical demand, ie, when the neutrophil count decreased to
less than 0.5 3 109/L and fever or other signs of infection were
present. Twenty-four patients in all (16.5%) received at least a
few days of therapy with G-CSF or GM-CSF.
Table 3 shows the toxicity associated with administration of
the drug regimen.
Hematologic toxicity was more severe (and more frequently
dose-limiting) than nonhematological side effects. Eleven pa-
tients (8%) required transfusion of at least 1 U of concentrated
erythrocytes. Thirty-seven febrile episodes were recorded
throughout the treatment of the 30 patients (21%; Table 3) who
registered at least one neutrophil count less than 0.5 3 109/L. In
this regard, the criteria adopted in 1992 for the use of growth
factors helped to limit the length and severity of serious
infections in the second part of the trial, but did not affect their
Table 3. Maximal Grades of Acute Hematological and
Nonhematological Toxicity Experienced by Patients
(Percentages of 145 Cases)
ECOG Grade
0 I II III IV
Hemoglobin 16 51 19 10 4
White blood cell count 0 25 32 26 17
Neutrophil count 0 20 29 30 21
Platelet count 9 14 21 29 27
Nausea and vomiting 21 28 37 14 0
Alopecia 12 29 32 27 0
Neurologic toxicity 26 47 20 7 0
Mucositis 45 48 7 0 0
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number throughout the study. One P carinii pneumonia, 1
cytomegalovirus infection, 1 acute B-virus hepatitis (likely
posttransfusional), and 2 cases of thoracic herpes zoster were
recorded; interruption of chemotherapy due to these illnesses
had no effect on clinical response. Seven subjects developed
prolonged asymptomatic pancytopenia, presenting a hemoglo-
bin level of less than 10.0 g/dL, a white blood cell count of less
than 2 3 109/L, and a platelet count of less than 100 3 109/L for
3 months or longer after the end of therapy.
Nonhematological toxicity was acceptable. Most of the cases
of grade 2-3 nausea and/or vomiting were recorded before the
antiserotoninergic receptor drugs became available, so that this
side effect can be considered well controlled. Neurotoxicity
required dose reduction of vincristine and vinblastine in 7
subjects. Mucositis was always mild. Two cases of pulmonary
fibrosis were observed: the first (of grade 2 intensity) occurred
during chemotherapy and was related to the administration of
bleomycin (which was promptly stopped); the second (of grade
3 intensity) became evident 2 months after radiotherapy. One
case of probable cardiotoxicity due to anthracycline consisting
of a reversible episode of flutter-fibrillation occurred in a
33-year-old patient during the second cycle. Epidoxorubicin
was omitted from this subject’s subsequent cycles.
RT was administered in 47 patients (32%), 46 of whom were
evaluated to be in CR or in CRu after completion of chemother-
apy. Patients received RT with different supervoltage equipment
in 13 distinct radiotherapy units. Dose fractions varied from
0.16 to 0.22 Gy and total doses ranged from 26 to 42 Gy
(median, 35 Gy). The number of irradiated anatomic sites was 1
in 21 patients, 2 in 12, and 3 in 4. The areas to be irradiated were
selected according to their bulky involvement at diagnosis or
slow or partial response to chemotherapy. Extended-field radio-
therapy was delivered in 10 patients (above the diaphragm in 9
and below the diaphragm in 1) either because of the extensive
and massive involvement of other lymph node sites besides the
one evaluated as bulky or because chemotherapy interruption
(for complications, patient refusal to continue, etc) was antici-
pated.
The median follow-up was 66 months (range, 25 to 114
months). Figure 1 shows the TM and OS and Fig 2 shows the
RFS and FFS recorded in the eligible study population. Table 4
offers a summary check of CR, PR, and death rates and OS, TM,
RFS, and FFS both in the 145 eligible patients and in the total
population of 155 subjects that were recruited and whom we
intended to treat. Differences shown in Table 4 were negligible,
and therefore only the eligible patients were analyzed. Of the 4
PR patients, 2 underwent high-dose chemotherapy with autolo-
gous bone marrow transplantation (1 was rescued and is still
alive in CR and 1 did not respond and subsequently died) and 2
responded poorly to additional therapies as well and still
survive with evidence of disease. The other 4 subjects with
nonresponding or progressive disease during chemotherapy
died within 5 months of diagnosis: 1 of complications to therapy
and 3 of the disease.
Among the 137 CR, 24 relapses were recorded. Five of these
24 patients underwent high-dose chemotherapy with autologous
bone marrow transplantation: 3 of them died of unresponsive
disease, 1 responded partially and is alive with evidence of
disease, and 1 achieved a new CR. The relapses of the other 19
were treated with different conventional regimens containing
three or four drugs or with alternating or hybrid ones delivering
six drugs or more; 8 patients obtained a new CR and 6 are still
alive (1 died of myelodysplastic syndrome and 1 died of
infections [the subject was human immunodeficiency virus
(HIV)-positive]), 1 responded partially to several subsequent
therapies and is alive with evidence of disease, and 10 died of
the disease after little or no response.
A synchronous tumor was diagnosed in 1 patient and
metachronous ones developed in 7 other subjects. The clinical
characteristics of these patients and the types of tumors
recorded are listed in Table 5. These patients shared no definite
clinical features, in particular not high drug dose intensity,
frequent association of RT, or elevated incidence of relapses
requiring further treatment. Both patients who developed small-
cell lung carcinoma were smokers.
In all, 18 patients died: 13 of HD progression after either
first-line CT failure or one or more relapses, 1 of a pulmonary
infection from Klebsiella pneumoniae in second CR (the
HIV-positive patient), 1 of severe gastric hemorrhage during CT
(to which the disease did not respond), and 3 of second tumors.
A large list of factors reputed to be important for HD
prognosis were scrutinized in a univariate analysis in relation to
OS, RFS, and FFS and are reported in Table 6. Surprisingly,
some of the best-known and most important prognostic factors
in HD, such as stage, presence of bulky disease, extranodal
Fig 1. Curves of TM and OS recorded in the 145 patients with
advanced HD treated with MOPPEBVCAD.
Fig 2. RFS and FFS curves of the study population.
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involvement, erythrocyte sedimentation rate, hemoglobin con-
centration, serum lactate dehydrogenase, serum albumin level,
and treatment with combined radiotherapy, did not influence
any of the survival time parameters. Those that were found to
exert a statistically significant role with respect to at least one
follow-up variable (age, histologic type, performance status,
bone marrow involvement, dose intensity of the first 3 CT
cycles, SNLG prognostic index, and IDHD 5-year OS estimate)
underwent multivariate analysis in the final Cox model, and
only age and histologic type retained good statistical impor-
tance for OS and FFS, with histology being the only decisive
factor for RFS (Table 7). When age was removed from the
model, its prognostic role was replaced by bone marrow
involvement and performance status for OS and by performance
status alone for FFS. Practically speaking, patients more than 45
to 50 years of age (or, alternatively, with involved bone marrow
and Karnofsky index #70) presenting lymphocyte depletion
histologic type have a high probability of poor or short-lasting
response.
Systematic calculation of the SNLG index at diagnosis for
each patient led to the identification of 52 subjects who had to
be considered at high risk (ie, with an index .0.5, correspond-
ing to a 60% probability of dying within 4 years, according to
the work of Proctor et al29). Survival of such high-risk subjects
(Fig 3) tended to be shorter than that of the other patients in the
series, but the difference was not statistically significant and the
survival plateaux, rather near each other, reached by both the
curves do not lead us to think that prolonging the observation
time would improve the statistical difference.
Moreover, the IDHD estimate of the probability of surviving
at any given time was computed for each subject and made it
possible to calculate the expected median survival of the whole
population for any given year with a 61 standard deviation
confidence interval. As shown in Fig 4, it is clear that the
MOPPEBVCAD protocol allows patients to survive longer than
expected, all clinical patient characteristics of the patients being
equal, with respect to the experience of the 1970s and 1980s.
DISCUSSION
The basic idea that underlay the formulation of the MOPP-
EBVCAD CT regimen, optionally combined with limited RT,
for advanced HD was to try to improve an already existing
treatment program, which had to be well known as widely
tested and highly effective, by introducing selected changes. In
1987, the GISL chose Straus’ alternating regimen23 as the
original reference model, because, in the middle 1980s, it
showed some of the relatively best figures for CR and RFS,
associated with less frequent nausea and vomiting (which were
serious clinical problems in those years). Importantly, these
results seemed to agree fully with the theoretical models of
drug sensitivity related to cell kinetics. Thus, hybridization of
the drugs of the alternating CAD/MOPP/ABV into the
MOPPEBVCAD schedule offered closer compliance with the
Goldie and Coldman theory.9
Contemporary intensification of doses was obtained by
administering in 6 cycles approximately the same cumulative
drug dosage delivered with 9 cycles of the alternating CAD/
MOPP/ABV and by reducing the cycle length from 35 to 28
days. The resulting planned intensification, according to the
criteria reported by Hryniuk,27 was 1.54. Therefore, the average
relative dose intensity actually delivered in our series with the
hybrid regimen, which was 0.72, corresponded to 1.10 of the
projected doses in the first 6 cycles of the reference regimen.
Because the average observed-to-expected total drug delivery
Table 4. Comparison of Results Obtained in the 145 Patients Eligible for the Study and in the Total Population of Subjects
That Were Recruited and Treated
Patients
Response
Deaths
Survival
TM OS RFS FFS
CR PR 3 yr 5 yr 3 yr 5 yr 3 yr 5 yr 3 yr 5 yr
Eligible (145) 0.944 0.028 0.124 0.915 0.889 0.908 0.881 0.833 0.814 0.845 0.786
All treated (155) 0.935 0.032 0.135 0.902 0.878 0.896 0.872 0.838 0.820 0.838 0.785
Table 5. Characteristics of Those Patients Who Developed a Second Cancer After HD
Patient
Sex/Age
(yr) Histology Stage Bulk RT
DI
(6 cycles)
Clinical
Response Relapse
Time*
(mo)
Present
Status
Second
Cancer
M.C. M/62 MC III B 1 2 0.76 CR 2 0 Deceased SCLC
M.G. M/71 LD IV B 2 2 0.68 CR 2 25 Alive Sigmoid carci-
noma
F.A. M/44 MC IIIS A 2 2 0.69 CR 1 50 Deceased RAEB
S.A. M/61 LD II B 1 1 0.67 CR 2 55 Deceased SCLC
G.P. M/43 NS IV A 2 2 0.68 CR 2 55 Alive RAEB
F.P. M/58 NS IV A 2 2 0.77 CR 2 60 Alive Colon carcinoma
G.M. F/29 MC III A 1 1 0.86 CR 1 62 Alive Frontal bone
eosinophilic
granuloma
S.F. F/27 NS III A 2 2 0.90 CR 2 77 Alive RAEB
The table also reports the patient whose second tumor, diagnosed at the end of therapy for HD, should properly be considered a synchronous
cancer (first line).
Abbreviations: DI, dose intensity; SCLC, small-cell lung cancer; RAEB, refractory anemia with excess of blasts.
*Time from the end of therapy to the diagnosis of second cancer.
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ratio during the initial 6 months with the alternating regimen
proved to be 0.81,23 a true dose intensification of about 36% was
actually reached with the hybridized CT regimen.
Conversely, to minimize early and late toxicity without
compromising results, CT intensification was coupled with a
marked reduction in the RT program. Whereas irradiation of all
nodal regions initially involved was provided between the sixth
and seventh cycle of the alternating CAD/MOPP/ABV regi-
men, only lesions evaluated as bulky at diagnosis or slowly or
partially responding during CT (which are the sites with the
highest probability of clinical failure) were irradiated after
hybrid MOPPEBVCAD. The consequence of this decision was
that about two thirds of our patients did not undergo RT and,
where it was used, only one or two anatomic sites (rarely more)
were irradiated.
Clinical results regarding the unfavorable subset of HD
patients are interesting, because consistently excellent figures
for CR rate, TM, OS, RFS, and FFS were achieved. Table 8 lists
the results of some of the major and recently reported series on
advanced HD. Even though true and exact comparisons cannot
be made among series with differences in patient composition,
length of follow-up, therapy duration (mainly, number of
cycles), and supportive care, our data seem to be similar to or
better than those from the best protocols with alternating or
hybrid chemotherapy. Only 2 of the 24 relapses in our study
were recorded after 36 months of follow-up and none after 43
months; thus, our initial reserve about long-term results can be
removed.
Furthermore, some of the most important and strongest
prognostic factors seemed to be mitigated or even eliminated by
this therapy: stage, bulky disease, involvement of the spleen or
extranodal sites, B systemic symptoms, high levels of LDH
and/or ESR, and low hemoglobin and/or serum albumin concen-
Fig 3. Survival comparison between the 52 patients having a
SNLG index greater than 0.5, ie, absolutely the best prognosis
according to Proctor et al,29 and the remaining 93 members of the
study population.
Fig 4. Survival curve of the 145 study patients together with a
band of 61 SD around the expected median survival, which was
estimated in the same patient series according to IDHD clinical
experience and computation techniques.30
Table 6. List of the Clinical Variables Analyzed With a Univariate
Technique in Relation to OS, RFS, and FFS
Clinical Variables
OS
(P)
RFS
(P)
FFS
(P)
Sex* .1744 .5736 .5230
Age† 4 3 1025 .1118 .0034
Histology ([LP 1 NS] v MC v LD) .0065 .0019 .0013
Stage (II v III v IV) .1566 .2503 .2607
Systemic symptoms* .7488 .5736 .7723
Karnofsky index† .0003 .2020 .0085
Bulky disease* .6047 .6805 .4041
Bone marrow involvement* .0005 .0472 .0077
Visceral involvement* .8196 .7952 .8052
ESR† .7235 .5916 .5435
Hb† .1795 .7675 .6559
LDH† .5742 .6926 .5763
Serum albumin† .6649 .3793 .8086
DI of CT cycles 1 to 3† .0346 .6931 .3905
DI of whole CT† .6236 .6900 .3691
Radiotherapy* .6242 .5227 .4193
SLNG prognostic index† .0006 .1972 .0396
IDHD 5-yr OS estimate† 7 3 1025 .0371 .0007
The reported levels of statistical significance derive from a log-rank
test for qualitative variables and from a likelihood ratio test in a
proportional hazards regression model for quantitative variables.
*Binary data, ie, present (male, given) or absent (female, not given).
†Data used in a continuous distribution.
Table 7. Clinical Characteristics Most Strictly Related to OS, RFS,
and FFS After MOPPEBVCAD (1RT)
Clinical
Covariates
OS
(P)
RFS
(P)
FFS
(P)
Age .0005 — — .0104 —
Histology .0671 .0862 .0012 .0016 .0019
Karnofsky index ..1 .0633 — ..1 .0257
Bone marrow
involvement ..1 .0021 ..1 ..1 ..1
DI of CT cycles 1-3 ..1 ..1 — — —
SLNG prognostic
index ..1 ..1 — ..1 ..1
IDHD 5-yr OS esti-
mate ..1 ..1 ..1 ..1 ..1
Results of multivariate analysis with a proportional hazards regres-
sion model. Covariates entering the study were the best ones emerg-
ing from univariate analysis (bold and italic fonts indicate statistical
probability of the null hypothesis ,.05 or ranging from .10 to .05,
respectively).
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tration proved to have no more influence on response to therapy,
survival, or probability of relapse in patients treated with
MOPPEBVCAD. This was particularly clear when outcome
data were tested while considering two powerful composite
prognostic systems, the IDHD survival estimate and the SNLG
prognostic index. The survival of patients treated with the
MOPPEBVCAD protocol exceeded the IDHD estimation of an
expected survival band of 1 standard deviation around the
median. Among patients treated with MOPPEBVCAD, there
were no longer clear differences in survival (and RFS or FFS)
between those with a SNLG prognostic index greater than 0.5
(whose probability of dying within 48 months should be 60%29)
and those with a lower index value.
With MOPPEBVCAD therapy, only two clinical factors
retain a crucial prognostic role: age and lymphocyte depletion
histologic type. However, in practice, it is clinically rather
difficult to use age to select those patients who are probably
destined to fail to respond to MOPPEBVCAD therapy for a
program of alternative experimental treatment. As a matter of
fact, nearly the same age limits that would identify higher-risk
patients should contraindicate such treatment options. Exclud-
ing age from the prognostic evaluation and accepting that it
should simply discriminate otherwise selected high-risk pa-
tients only on the grounds of the technical feasibility of
probably investigational therapy, the second and third most
unfavorable prognostic factors for patients treated with
MOPPEBVCAD become performance status and bone marrow
involvement at diagnosis. Performance status can be accepted
as a sufficiently useful factor because, first, it is not necessarily
in conflict with other treatment options, even transplantation
(being subject to pre-therapy improvement, if necessary) and,
second, its highest discriminant effect is placed between 70 and
80 of the Karnofsky scale (ECOG, 1 to 2). Therefore, apart from
age greater than 45 to 50 years, patients with lymphocyte
depletion histologic type, bone marrow involvement, and/or
Karnofsky index #70 (or ECOG grade #2) should enter
clinical trials to compare one of the best chemotherapy regi-
mens developed so far with one of the most promising
experimental treatments available. Caution is needed when
considering these prognostic results, despite the highly signifi-
cant statistical levels reached, because they actually derive from
a low number of observed failures. These results require further
confirmation.
It is likely that the development of treatment protocols with
increasing effectiveness in HD will require a search for
particular prognostic factors related to a given CT regimen.
Consideration of these features, according to the specific
treatment one intends to use, would be important for early
selection of patients with a definite risk for specifically designed
clinical trials.
A few comments are needed on results and toxicity.
Acute nonhematological toxicity has to be considered fully
acceptable and comparable with that of many alternating or
hybrid regimens containing seven to eight drugs or more.
Hematological toxicity was remarkable but controllable. First
of all, only 1 toxic death was recorded, from gastrointestinal
hemorrhage, in a man who did not show a response and
presented severe thrombocytopenia after the second cycle of
therapy. Second, growth factors, which became available during
the last 2 years of the trial, were used only on demand in a strict
minority of patients (16%). It is likely that moderate and
intelligent use of them can contribute to reducing the conse-
quences of myelotoxicity, particularly those related to heavy
neutropenia.
Finally, as for intermediate and late toxicity, 1 case of
nonsevere pulmonary fibrosis, 1 of mild cardiotoxicity (recur-
rent accesses of atrial fibrillation), and 7 second cancers (3 of
which were fatal) were diagnosed during the follow-up. Al-
though this series might not be considered completely mature in
this regard, the absolute incidence per type of cancer appears to
be lower than what is generally expected when dealing with
MOPP and MOPP derivatives and probably higher than that
recorded with ABVD. Staging without splenectomy, shortening
the time of CT administration, reducing cumulative individual
drug doses scheduled in the original alternating regimen from
which MOPPEBVCAD derives, and eliminating RT in the
majority of patients (with a reduction of the irradiated areas in
the remaining ones) are all factors that potentially lower the
relative risk of second cancer. Actually, the planned dose
intensity for each drug in MOPPEBVCAD CT is not absolutely
Table 8. Results of Some of the Main Alternating or Hybrid Multiple-Drug CT Regimens in the Treatment of Advanced HD
Study Treatment
No. of
Patients
CR
(%) OS RFS FFS
Follow-Up
(median,
mo)
Canellos et al17 MOPP (no RT) 123 67 66 — 50 60
ABVD (no RT) 115 82 73 — 61 60
MOPP/ABVD alt. (no RT) 123 83 75 — 65 60
Hancock et al15 LOPP 1 IF RT 295 57 66 52 — 60
LOPP/EVAP alt. 1 IF RT 299 64 75 72 — 60
Cullen et al16 ChlVPP/PABIOE 1 IF RT 216 85 78 — 68 60
Radford et al20 * MVPP 1 IF RT 208 58 71 — (PFS: 66) 54
ChlVPP/EVA hybr. 1 IF RT 211 72 80 — (PFS: 80) 54
Bartlett et al41 MDVPVBE (Stanford V) (1IF RT) 65 — 96 — 87 24
Viviani et al19 MOPP/ABVD alt. 1 IF RT 211 91 74 74 67 108
MOPP/ABVD hybr. 1 IF RT 204 89 72 76 69 108
Diehl et al21 BEACOPP 1 IF RT 30 93 96 96 89 40
Martinelli et al40 ChlVPP/ABVVp16 28 95 75 — 70 48
This series MOPPEBVCAD (1IF RT) 145 94 86 82 78 66
*Fifteen percent of the patients with stage IB-IIA.
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high when compared with what is commonly delivered in other
popular CT regimens for HD. For example, the 6-cycle
cumulative dose of mechlorethamine and vincristine is 25% and
that of procarbazine 50% of what is provided in 6 cycles of the
MOPP regimen1; the total dose of vinblastine and epidoxorubi-
cin (assumed to be equivalent to a 40% lower dose of
doxorubicin35) is 50% and that of bleomycin is 75% of what is
planned in 6-cycle ABVD therapy2; CCNU doses are 50% of
those delivered in the CVPP regimen36 or 66% of those in CEP37
CT. Finally, the cumulative dose of melphalan represents 70%
of what is administered to patients with multiple myeloma over
the same period at a current dosage of 0.25 mg/kg/d for 4 days
every 6 weeks. On the other hand, a relatively high proportion
of elderly patients (21% .50 years of age), advanced stage
disease, increased dose intensity, association of several, albeit
different, and potentially leukemogeneic drugs can be factors
favoring the onset of a second cancer.
Unfortunately, the majority of the available studies on second
cancer incidence among HD patients either involve too long a
period of recruitment to reach a sufficient number of partici-
pants and unavoidably collect heterogeneously treated patients
or are focused on relative risk with respect to a control
population. The information we need for each trial (and for each
arm of randomized studies) is represented by the number of
second cancers actually recorded (or their cumulative inci-
dence) and by the actual median follow-up length, but the
availability of both in the literature is not common.
Indeed, our incidences of second myelodysplasia (2.1%),
truly secondary lung cancer (0.7%), and colorectal cancer
(1.4%) are similar to those of Viviani et al19 after alternating or
hybrid MOPP/ABVD with or without RT, ie, 2.6%, 0.9%, and
0.5%, respectively. The experience of the Royal Marsden
Hospital investigators38 after MOPP or MOPP-derived regi-
mens also seems to be comparable, because the cumulative
incidence at 5 and 10 years is 0.6 and 1.9 for second leukemia
and related disorders, 0.2 and 1.3 for lung cancer, and 1.7 and
2.3 for other solid tumors, excluding skin cancers, respectively.
The data on actuarial risk for second leukemia, lung cancer, and
solid tumors that can be extrapolated from the study by
Abrahamsen et al,39 on a population of patients with all disease
stages, and from that by Martinelli et al,40 on advanced-stage
patients only, are fully comparable, too. Thus, MOPPEBVCAD
does not carry a higher risk of secondary tumors than what is
observed in other series of patients treated with other alternating
or hybrid drug combinations.
Only 2 patients in our series had relapsed before the onset of
second cancer, so a role for extended administration of poten-
tially oncogenic drugs as salvage therapy can be claimed in a
minority of patients. Similarly, only the patient who developed
lung cancer and the one who suffered a unifocal eosinophilic
granuloma were treated with both CT and RT; therefore, this
combined therapy cannot be considered a major causative
factor.
Fertility was not specifically studied in these high-risk
patients. Nevertheless, it is known to have been preserved in
some of them. A 26-year-old woman and a 35-year-old man
generated normal offspring 29 and 38 months, respectively,
after treatment.
In conclusion, MOPPEBVCAD CT with optional limited RT
can be considered a highly effective protocol for advanced HD.
Its early hematologic toxicity is equivalent to that of other
alternating or hybrid seven- or eight-drug regimens and might
be better controlled with a limited use of growth factors. Its late
toxicity is at least no greater than that of other alternating or
hybrid regimens, particularly those including MOPP drugs.
Randomized studies are needed and two are currently under
way to compare other popular regimens with MOPPEBVCAD
and to explore a less toxic version of it.
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